News Image

NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

By Mill Chart

Last update: Apr 5, 2024

Exploring Growth Potential: HALOZYME THERAPEUTICS INC (NASDAQ:HALO) and Its Base Formation. Growth investors seek promising revenue and EPS growth, and HALOZYME THERAPEUTICS INC has come under our scrutiny for potential growth investing. While it's crucial to do your own research, we've detected HALOZYME THERAPEUTICS INC on our screen for growth with base formation, suggesting it merits a closer look.

Exploring NASDAQ:HALO's Growth

Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NASDAQ:HALO boasts a 9 out of 10:

  • HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.23%, which is quite impressive.
  • Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 45.64% on average per year.
  • The Revenue has grown by 25.59% in the past year. This is a very strong growth!
  • The Revenue has been growing by 40.42% on average over the past years. This is a very strong growth!
  • Based on estimates for the next years, HALO will show a very strong growth in Earnings Per Share. The EPS will grow by 20.73% on average per year.
  • The Revenue is expected to grow by 11.91% on average over the next years. This is quite good.

How We Gauge Health for NASDAQ:HALO

ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:HALO was assigned a score of 7 for health:

  • HALO has an Altman-Z score of 3.47. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • HALO has a Altman-Z score of 3.47. This is in the better half of the industry: HALO outperforms 75.04% of its industry peers.
  • HALO has a Debt to FCF ratio of 4.02. This is amongst the best in the industry. HALO outperforms 95.04% of its industry peers.
  • A Current Ratio of 6.64 indicates that HALO has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.64, HALO is doing good in the industry, outperforming 65.30% of the companies in the same industry.
  • A Quick Ratio of 5.50 indicates that HALO has no problem at all paying its short term obligations.

Profitability Insights: NASDAQ:HALO

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:HALO, the assigned 7 is noteworthy for profitability:

  • With an excellent Return On Assets value of 16.25%, HALO belongs to the best of the industry, outperforming 98.97% of the companies in the same industry.
  • HALO has a Return On Equity of 335.99%. This is amongst the best in the industry. HALO outperforms 100.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 17.00%, HALO belongs to the top of the industry, outperforming 98.46% of the companies in the same industry.
  • HALO had an Average Return On Invested Capital over the past 3 years of 17.78%. This is above the industry average of 13.58%.
  • The Profit Margin of HALO (33.96%) is better than 99.15% of its industry peers.
  • HALO has a better Operating Margin (41.02%) than 99.32% of its industry peers.
  • HALO has a better Gross Margin (76.82%) than 85.98% of its industry peers.

How does the Setup look for NASDAQ:HALO

In addition to the Technical Rating, ChartMill provides a Setup Rating for each stock. This rating, ranging from 0 to 10, assesses the extent of consolidation in the stock based on multiple short-term technical indicators. Currently, NASDAQ:HALO has a 8 as its setup rating:

Although the technical rating is only medium, HALO does present a nice setup opportunity. We see reduced volatility while prices have been consolidating in the most recent period. A pullback is taking place, which may present a nice opportunity for an entry. There is a support zone below the current price at 39.72, a Stop Loss order could be placed below this zone.

Every day, new Strong Growth stocks can be found on ChartMill in our Strong Growth screener.

Our latest full fundamental report of HALO contains the most current fundamental analsysis.

For an up to date full technical analysis you can check the technical report of HALO

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (5/29/2024, 7:08:09 PM)

After market: 41.8 -0.96 (-2.25%)

42.76

-0.32 (-0.74%)

HALO News

News Imagea day ago - ChartmillNASDAQ:HALO is probably undervalued for the fundamentals it is displaying.

In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.

News Image9 days ago - Halozyme Therapeutics, Inc.Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee...

News Image13 days ago - Market News VideoHALO July 19th Options Begin Trading
News Image14 days ago - Investor's Business DailyHalozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating

On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.

News Image16 days ago - Investor's Business DailyCatalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating

On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.

News Image16 days ago - ChartmillWhile growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.

Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.

News Image21 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...

News Image21 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...

News Image21 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in May 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

News Image22 days ago - Halozyme Therapeutics, Inc.Halozyme to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present...

News Image22 days ago - InvestorPlaceHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image22 days ago - BusinessInsiderHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Halozyme Therapeutics (NASDAQ:HALO) just reported results for the first quarter...

HALO Links
Follow us for more